The reversible epigenetic silencing of BRM: implications for clinical targeted therapy.
about
SS18 together with animal-specific factors defines human BAF-type SWI/SNF complexesThe chromatin remodelling factor BRG1 is a novel binding partner of the tumor suppressor p16INK4aHDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory DiseasesRole of BAF60a/BAF60c in chromatin remodeling and hepatic lipid metabolismSWI/SNF chromatin remodeling complexes and cancerThe disparate origins of ovarian cancers: pathogenesis and prevention strategies.The SWI/SNF ATPases Are Required for Triple Negative Breast Cancer Cell ProliferationCoexistent loss of INI1 and BRG1 expression in a rhabdoid renal cell carcinoma (RCC): implications for a possible role of SWI/SNF complex in the pathogenesis of RCC.Mutations of Chromatin Structure Regulating Genes in Human Malignancies.Association of BRM promoter polymorphisms and esophageal adenocarcinoma outcomeChromatin-regulating proteins as targets for cancer therapy.Flavonoids from each of the six structural groups reactivate BRM, a possible cofactor for the anticancer effects of flavonoidsMethylation patterns of Brahma during spermatogenesis and oogenesis: potential implications.The silencing of the SWI/SNF subunit and anticancer gene BRM in Rhabdoid tumorsModulation of Brahma expression by the mitogen-activated protein kinase/extracellular signal regulated kinase pathway is associated with changes in melanoma proliferation.MITF-independent pro-survival role of BRG1-containing SWI/SNF complex in melanoma cells.Insertion/deletion polymorphisms in the promoter region of BRM contribute to risk of hepatocellular carcinoma in Chinese populations.ATP-dependent chromatin remodeling: genetics, genomics and mechanisms.Complex alternative splicing of the smarca2 gene suggests the importance of smarca2-B variantsSWItching on the transcriptional circuitry in melanoma.Oxidative stress induced lung cancer and COPD: opportunities for epigenetic therapy.Epigenetically maintained SW13+ and SW13- subtypes have different oncogenic potential and convert with HDAC1 inhibition.Two novel BRM insertion promoter sequence variants are associated with loss of BRM expression and lung cancer risk.Concomitant loss of SMARCA2 and SMARCA4 expression in small cell carcinoma of the ovary, hypercalcemic typeThe clinical significance of SWI/SNF complex in pancreatic cancer.Discovery of BRM Targeted Therapies: Novel Reactivation of an Anti-cancer GeneSWI/SNF-Mediated Lineage Determination in Mesenchymal Stem Cells Confers Resistance to Osteoporosis.Hijacking the chromatin remodeling machinery: impact of SWI/SNF perturbations in cancer.Mechanism of BRG1 silencing in primary cancers.Two BRM promoter insertion polymorphisms increase the risk of early-stage upper aerodigestive tract cancers.Vulnerabilities of mutant SWI/SNF complexes in cancer.Chromatin remodeler mutations in human cancers: epigenetic implications.Essential role of BRG, the ATPase subunit of BAF chromatin remodeling complexes, in leukemia maintenance.Oncogenic targeting of BRM drives malignancy through C/EBPβ-dependent induction of α5 integrin.Beyond Mutations: Additional Mechanisms and Implications of SWI/SNF Complex Inactivation.Driver mutations of cancer epigenomes.Phospho-ΔNp63α/microRNA network modulates epigenetic regulatory enzymes in squamous cell carcinomasEpigenomic regulation of oncogenesis by chromatin remodeling.Marked for death: targeting epigenetic changes in cancer.Identifying targets for the restoration and reactivation of BRM.
P2860
Q21134718-5E05F9B3-F293-4CE9-A1DA-67CE9A6EE291Q24317334-6C45DF4F-8339-4C8B-9DCC-50CA3D605050Q26739120-774C84DD-88CB-4650-B57D-C51F8303D02EQ26749020-99BD9529-8607-4C57-B98F-FC7934450630Q26998657-76FE73BE-6C00-4B71-9ACC-56024CA5C7C5Q30240709-3D3A7762-701E-480C-BB84-61047828A5E2Q30659086-2F707970-014F-4062-9D60-ECA4BB3350FDQ33583093-2C37DAC0-646F-4218-8ADD-1BF092C65706Q33600399-3ADADCE9-C452-4FD0-A99D-EDB0FFD0D86FQ33709588-99213730-988D-4885-AFEB-7F1DFD9F88AEQ33907067-4574D303-DCFB-40C9-A63F-31F25C170E79Q34260197-309D2D35-62F1-4C2A-9925-D34C03D87ADFQ34372557-EFC41D50-04CA-4D8B-AAA0-B6139A78EFC0Q34423814-B6C83430-9344-44AE-9E7D-0F3769A57250Q34459131-E7CD17A1-6706-464F-8229-C6876AA4F78AQ34562607-A2A8A05C-54C5-498A-9A7B-417E2A7FBD80Q34566605-8061A8CE-182D-45BF-8C0F-D2DB66EDC3CBQ34627244-462DDAD1-58BB-4A14-BA48-8042FA1B89EAQ35142978-54FBE8C0-C229-44E8-9BB5-35D8F47C6893Q35592205-FD4D676B-D661-4E41-87AC-39E412B6A0DCQ35841917-117A29F6-591B-4323-8EC3-BA72D2A0489DQ36020172-8B3DD5D3-58A7-4C3D-A19F-D028EF4EF10EQ36103995-510DDB48-32A4-4EA2-B54A-25B684A1A100Q36420683-F7B1581E-587B-4096-8474-81272E176514Q36642885-6CEB8C39-E8AB-4988-8D59-FBD75C2199B1Q36737338-76338E8E-6051-464D-80CD-7FCDE9C21D1AQ37238318-4F7A39AC-805D-4835-BE7E-ADF2C3C40D10Q37618471-2503C75A-FC16-4B65-97C8-03AB9852F7C6Q37636601-C2E0508D-4D1A-41B3-96D2-D08F81046BD4Q37703407-B73F97F7-1D9F-49DD-9976-FB8AB401FFEAQ38247363-4D2DFAFB-62B0-42E1-8C29-A856C37D3F0CQ38261746-43DBED98-89C0-49A4-A2C9-CCCA0BA60884Q38272367-B33D7B06-DDDC-4AB0-AC62-00B8129B156EQ38366100-2EB76386-3448-48E9-84EB-F7F613617738Q38379487-C00D6584-5C87-43E1-9AD7-DBE836AFB502Q38639828-2BABC37B-36E0-4244-AF30-AC3D47F6A29DQ38663683-34B2C390-293A-442F-91E1-AFA960522762Q38709544-3679D86B-0748-4286-9B08-97B1FC69B887Q38747872-0337E497-3DF2-42AA-BF72-A77286FB9861Q39176522-2F3AB80C-5F24-4A5D-84A3-0609A9A39BDE
P2860
The reversible epigenetic silencing of BRM: implications for clinical targeted therapy.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
The reversible epigenetic silencing of BRM: implications for clinical targeted therapy.
@en
The reversible epigenetic silencing of BRM: implications for clinical targeted therapy.
@nl
type
label
The reversible epigenetic silencing of BRM: implications for clinical targeted therapy.
@en
The reversible epigenetic silencing of BRM: implications for clinical targeted therapy.
@nl
prefLabel
The reversible epigenetic silencing of BRM: implications for clinical targeted therapy.
@en
The reversible epigenetic silencing of BRM: implications for clinical targeted therapy.
@nl
P2093
P356
P1433
P1476
The reversible epigenetic silencing of BRM: implications for clinical targeted therapy.
@en
P2093
Cirrincione GM
Michael CW
Muchardt C
P2860
P2888
P304
P356
10.1038/SJ.ONC.1210514
P407
P577
2007-06-04T00:00:00Z